CINC
Sign in
CinCor Pharma, Inc.
Save
1.27B
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F.
Similar securities
Based on sector and market capitalization
Report issue